Surrozen, Inc. (SRZN)
| Market Cap | 507.71M +323.1% |
| Revenue (ttm) | 11.51M -8.8% |
| Net Income | -324.56M |
| EPS | -32.19 |
| Shares Out | 17.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,648 |
| Open | 29.16 |
| Previous Close | 29.04 |
| Day's Range | 27.96 - 30.30 |
| 52-Week Range | 11.39 - 37.83 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 47.50 (+63.68%) |
| Est. Earnings | Nov 13, 2026 |
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular ag... [Read more]
Financial Performance
In 2025, Surrozen's revenue was $3.48 million, a decrease of -67.37% compared to the previous year's $10.66 million. Losses were -$242.03 million, 280.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SRZN stock is "Strong Buy." The 12-month stock price target is $47.5, which is an increase of 63.68% from the latest price.
News
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of...
Surrozen announces FDA clearance of IND application for SZN-8141
Surrozen (SRZN) announced its Investigational New Drug, IND, application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunct...
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross p...
Surrozen price target raised to $54 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Surrozen (SRZN) to $54 from $44 and keeps a Buy rating on the shares. The firm believes Merck’s (MRK) remigromig data “provides…
Surrozen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
SZN-8141, a dual Wnt/VEGF modulator, is entering clinical trials for retinal diseases, with the DUET study set to compare it to Vabysmo and focus on efficacy, durability, and retinal reperfusion. Strong IP, robust financing, and a pipeline including SZN-8143 and a candidate for Fuchs' dystrophy support growth.
Surrozen Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A two-part clinical study for a dual VEGF/Wnt molecule in DME will start this year, focusing on safety, efficacy, and unique reperfusion endpoints, with initial data expected in 2027. The program is supported by strong preclinical results, robust IP, and upcoming financing, while the competitive landscape is shaped by imminent phase III data from a similar Wnt agonist.
Surrozen submits investigational new drug application for SZN-8141
Surrozen (SRZN) announced the submission of an investigational new drug application to the FDA seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor antagonis...
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power o...
Surrozen Slides: Corporate presentation
Surrozen has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Surrozen to Present at Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the pow...
Surrozen initiated with an Outperform at William Blair
William Blair analyst Lachlan Hanbury-Brown initiated coverage of Surrozen (SRZN) with an Outperform rating and $51 fair value estimate. Surrozen is a biotechnology company developing multispecific an...
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipate...
Surrozen Quarterly report: Q2 2026
Surrozen has published its Q2 2026 quarterly earnings report on August 6, 2026.
Surrozen Earnings release: Q2 2026
Surrozen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Surrozen Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
The discussion highlighted the scientific rationale for targeting Frizzled-4 and Wnt signaling in retinal diseases, emphasizing the synergy of dual and tri-specific antibodies addressing VEGF, Wnt, and IL-6 pathways. Preclinical data show promise for improved fluid resolution and reperfusion, with clinical development focused on DME and potential expansion to other retinal conditions.
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026
Surrozen Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The platform leverages Wnt pathway biology to address unmet needs in retinal vascular diseases, with lead asset SZN-8141 combining Wnt agonism and VEGF inhibition for potentially superior retinal drying and vessel regrowth. Clinical validation is anticipated in the second half of the year, with significant market opportunity due to ongoing unmet needs.
Surrozen Transcript: AGM 2026
The meeting confirmed a quorum and covered four agenda items, including director elections, auditor ratification, and executive compensation. All proposals passed, with directors elected through 2029 and annual advisory votes on compensation approved.
Surrozen price target raised to $44 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Surrozen (SRZN) to $44 from $36 and keeps a Buy rating on the shares. The firm cites Surrozen’s continued platform progress towards…
Surrozen reports Q1 EPS ($11.65) vs. ($7.43) last year
Reports Q1 revenue $5M, consensus $4M. The company said, “Surrozen (SRZN) remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway…
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH S...
Surrozen Earnings release: Q1 2026
Surrozen released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Surrozen Quarterly report: Q1 2026
Surrozen has published its Q1 2026 quarterly earnings report on May 6, 2026.
Surrozen Slides: Corporate presentation
Surrozen has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Surrozen management to meet with Cantor
Luncheon Meeting with Management to be held in Denver on May 4 hosted by Cantor.